Working to eradicate dengue fever

April 13, 2009 by Carol C. Bradley

(PhysOrg.com) -- A research project led by University of Notre Dame biologist Malcolm J. Fraser Jr. may soon lead to the eradication of dengue fever, a mosquito-borne viral disease that annually infects more than 50 million people worldwide.

It began with an idea, Fraser says, and a grant from a Bill and Melinda Gates Foundation initiative, Grand Challenges in Global Health. These grants fund innovative research on scientific problems that—if solved—could lead to advances against multiple diseases.

“I chose dengue because I’m a virologist by training,” says Fraser, a professor of biological sciences. “I had this idea floating in my head for several years that one could target a in cells using a ribonucleic acid (RNA) enzyme known as ribozyme.”

Of those infected with , about 1.25 million each year will die. Dengue is spread between humans by the bite of Aedes aegypti, the mosquito species also known for transmitting .

Normally, when the cells of a mosquito become infected with the disease, the virus spreads to other cells, amplifying the virus.
“And then the virus gets transmitted to a human when the mosquito takes a blood meal,” Fraser explains. “That’s the way the mosquito acts as a vector for the virus.”

Fraser and his team of researchers have been successful in developing a ribozyme effector gene—a gene that effects the suppression of dengue virus in mosquito cells.

Fraser’s strategy arms mosquito cells with the ribozyme, so that if cells become infected with dengue, the ribozyme attacks the virus’ RNA genome, creating new molecules that cause the cell to die.

So far, the strategy is working.

And the potential is exciting, Fraser says. While his current research may result in the creation of mosquitoes incapable of transmitting dengue fever, he also can see the same strategy being used to combat two other human virus diseases—HIV and .

The next step in the dengue fever research will involve developing and testing transgenic mosquitoes.

“Our goal is to show that these mosquitoes cannot transmit the disease because they are protected from infection by this ribozyme,” he says. “If we can demonstrate that, then we have to figure out whether the protection is stable over the long term—over many generations.”

While Fraser is confident that he can create transgenic mosquitoes that do not transmit the disease, the critical problem will be replacing disease-carrying mosquitoes with the transgenic mosquitoes in areas where dengue is endemic.

“We need to basically do a population replacement, or as close to a population replacement as we can get,” he says.

Fraser’s research will likely be consolidated with another research project—focusing on introducing transgenic mosquitoes into the environment—conducted by a group at the University of California Irvine.

“It’s a natural congruence. I have the effector molecule and can make transgenic mosquitoes. They’ve been studying how we can get transgenic mosquitoes to become the predominate population. We needed to come together at some point to actually bring this to fruition,” Fraser explains.

The research is something that he couldn’t have done without the support of the Gates Foundation, he adds. “They gave me the chance to explore this. I had an idea, and they funded it.”

It’s one thing to study science for the sake of science, Fraser says.

“I’d rather be doing science that will help people. Not 70 years from now, but in my lifetime. I’m very excited that I may be able to do that. We may have a way of controlling dengue fever in the next 10 years.”

Provided by University of Notre Dame (news : web)

Related Stories

Recommended for you

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

Migraines may be the brain's way of dealing with oxidative stress

October 19, 2017
A new perspective article highlights a compelling theory about migraine attacks: that they are an integrated mechanism by which the brain protects and repairs itself. Recent insightful findings and potential ways to use them ...

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.